Effects of menopausal hormone therapy-based on the role of estrogens, progestogens, and their metabolites in proliferation of breast cancer cells

Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, et al. Postmenopausal hormone therapy: an endocrine society scientific statement. J Clin Endocrinol Metab. 2010; 95: s1-66.

Stramba-Badiale M. Postmenopausal hormone therapy and the risk of cardiovascular disease. J Cardiovasc Med (Hagerstown). 2009; 10: 303-9.

Santoro N, Epperson CN, Mathews SB. Menopausal symptoms and their management. Endocrinol Metab Clin North Am. 2015; 44: 497-515.

Baber RJ, Panay N, Fenton A. 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016; 19: 109-50.

Stanczyk FZ. Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Rev Endocr Metab Disord. 2002; 3: 211-24.

Sitruk-Ware R. Pharmacological profile of progestins. Maturitas. 2004; 47: 277-83.

Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, et al. Classification and pharmacology of progestins. Maturitas. 2008; 61: 171-80.

Brisken C, Hess K, Jeitziner R. Progesterone and overlooked endocrine pathways in breast cancer pathogenesis. Endocrinology. 2015; 156: 3442-50.

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women’s health initiative randomized controlled trial. JAMA. 2002; 288: 321-33.

Beral V. Breast cancer and hormone-replacement therapy in the million women study. Lancet. 2003; 362: 419-27.

Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-epic cohort. Int J Cancer. 2005; 114: 448-54.

Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study. Breast Cancer Res Treat. 2008; 107: 103-11.

Santen RJ, Yue W. Cause or prevention of breast cancer with estrogens: Analysis from tumor biologic data, growth kinetic model and women’s health initiative study. Climacteric. 2019; 22: 3-12.

Santen RJ, Yue W, Heitjan DF. Modeling of the growth kinetics of occult breast tumors: role in interpretation of studies of prevention and menopausal hormone therapy. Cancer Epidemiol Biomarkers Prev. 2012; 21: 1038-48.

Dallal CM, Tice JA, Buist DS, Bauer DC, Lacey Jr JV, Cauley JA, et al. Estrogen metabolism and breast cancer risk among postmenopausal women: a case-cohort study within B~FIT. Carcinogenesis. 2014; 35: 346-55.

Mackey RH, Fanelli TJ, Modugno F, Cauley JA, McTigue KM, Brooks MM, et al. Hormone therapy, estrogen metabolism, and risk of breast cancer in the women’s health initiative hormone therapy trial. Cancer Epidemiol Biomarkers Prev. 2012; 21: 2022-32.

Trabert B, Bauer DC, Buist DSM, Cauley JA, Falk RT, Geczik AM, et al. Association of circulating progesterone with breast cancer risk among postmenopausal women. JAMA Netw Open. 2020; 3: e203645.

Miao S, Yang F, Wang Y, Shao C, Zava DT, Ding Q, et al. 4-Hydroxy estrogen metabolite, causing genomic instability by attenuating the function of spindle-assembly checkpoint, can serve as a biomarker for breast cancer. Am J Transl Res. 2019; 11: 4992-5007.

Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The women’s health initiative randomized controlled trial. JAMA. 2004; 291: 1701-12.

LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011; 305: 1305-14.

Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women’s health initiative randomized trials. JAMA. 2013; 310: 1353-68.

Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the women’s health initiative randomized trials. JAMA. 2017; 318: 927-38.

Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012; 345: e6409.

Bakken K, Fournier A, Lund E, Waaseth M, Dumeaux V, ClavelChapelon F, et al. Menopausal hormone therapy and breast cancer risk: impact of different treatments. The european prospective investigation into cancer and nutrition. Int J Cancer. 2011; 128: 144-56.

Fournier A, Mesrine S, Dossus L, Boutron-Ruault MC, ClavelChapelon F, Chabbert-Buffet N. Risk of breast cancer after stopping menopausal hormone therapy in the e3n cohort. Breast Cancer Res Treat. 2014; 145: 535-43.

Holm M, Olsen A, Au Yeung SL, Overvad K, Lidegaard Ø, Kroman N, et al. Pattern of mortality after menopausal hormone therapy: long-term follow up in a population-based cohort. BJOG. 2019; 126: 55-63.

Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases. BMJ. 2020; 371: m3873.

Gompel A, Plu-Bureau G. Progesterone, progestins and the breast in menopause treatment. Climacteric. 2018; 21: 326-32.

Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 1997; 138: 863-70.

Denver N, Khan S, Stasinopoulos I, Church C, Homer NZ, MacLean MR, et al. Derivatization enhances analysis of estrogens and their bioactive metabolites in human plasma by liquid chromatography tandem mass spectrometry. Anal Chim Acta. 2019; 1054: 84-94.

Gustafsson JA. What pharmacologists can learn from recent advances in estrogen signalling. Trends Pharmacol Sci. 2003; 24: 479-85.

Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, et al. Mechanisms of estrogen action. Physiol Rev. 2001; 81: 1535-65.

Wilkenfeld SR, Lin C, Frigo DE. Communication between genomic and non-genomic signaling events coordinate steroid hormone actions. Steroids. 2018; 133: 2-7.

Hayashi S, Yamaguchi Y. Estrogen signaling pathway and hormonal therapy. Breast Cancer. 2008; 15: 256-61.

Lösel R, Wehling M. Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol. 2003; 4: 46-56.

Losel RM, Falkenstein E, Feuring M, Schultz A, Tillmann HC, Rossol-Haseroth K, et al. Nongenomic steroid action: controversies, questions, and answers. Physiol Rev. 2003; 83: 965-1016.

Saczko J, Michel O, Chwilkowska A, Sawicka E, Maczynska J, Kulbacka J. Estrogen receptors in cell membranes: regulation and signaling. Adv Anat Embryol Cell Biol. 2017; 227: 93-105.

Levin ER. Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol. 2003; 17: 309-17.

Giuliano M, Trivedi MV, Schiff R. Bidirectional crosstalk between the estrogen receptor and human epidermal growth factor receptor 2 signaling pathways in breast cancer: molecular basis and clinical implications. Breast Care (Basel). 2013; 8: 256-62.

Raffo D, Pontiggia O, Bal de Kier Joffe E, Simian M. Non-genomic actions of estradiol and 4-OH-tamoxifen on murine breast cancer cells. Oncol Rep. 2015; 33: 439-47.

Aronica SM, Kraus WL, Katzenellenbogen BS. Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc Natl Acad Sci U S A. 1994; 91: 8517-21.

Garrido P, Morán J, Alonso A, González S, González C. 17β-estradiol activates glucose uptake via GLUT4 translocation and PI3K/Akt signaling pathway in MCF-7 cells. Endocrinology. 2013; 154: 1979-89.

Carmeci C, Thompson DA, Ring HZ, Francke U, Weigel RJ. Identification of a gene (GPR30) with homology to the G-proteincoupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics. 1997; 45: 607-17.

Yang H, Wang C, Liao H, Wang Q. Activation of GPER by E2 promotes proliferation, invasion and migration of breast cancer cells by regulating the miR-124/CD151 pathway. Oncol Lett. 2021; 21: 432.

Filardo EJ, Quinn JA, Bland KI, Frackelton Jr AR. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol. 2000; 14: 1649-60.

Vivacqua A, Romeo E, De Marco P, De Francesco EM, Abonante S, Maggiolini M. GPER mediates the Egr-1 expression induced by 17β-estradiol and 4-hydroxitamoxifen in breast and endometrial cancer cells. Breast Cancer Res Treat. 2012; 133: 1025-35.

Deng Y, Miki Y, Nakanishi A. Estradiol/GPER affects the integrity of mammary duct-like structures in vitro. Scientific Reports. 2020; 10: 1386.

Santen RJ, Yue W, Wang J-P. Estrogen metabolites and breast cancer. Steroids. 2015; 99: 61-6.

Samavat H, Kurzer MS. Estrogen metabolism and breast cancer. Cancer Lett. 2015; 356: 231-43.

Gupta M, McDougal A, Safe S. Estrogenic and antiestrogenic activities of 16alpha- and 2-hydroxy metabolites of 17beta-estradiol in MCF-7 and T47D human breast cancer cells. J Steroid Biochem Mol Biol. 1998; 67: 413-9.

Suto A, Telang NT, Tanino H, Takeshita T, Ohmiya H, Osborne MP, et al. In vitro and in vivo modulation of growth regulation in the human breast cancer cell line MCF-7 by estradiol metabolites. Breast Cancer. 1999; 6: 87-92.

Yager JD. Mechanisms of estrogen carcinogenesis: the role of E2/E1-quinone metabolites suggests new approaches to preventive intervention--a review. Steroids. 2015; 99: 56-60.

Lareef MH, Garber J, Russo PA, Russo IH, Heulings R, Russo J. The estrogen antagonist ICI-182-780 does not inhibit the transformation phenotypes induced by 17-beta-estradiol and 4-OH estradiol in human breast epithelial cells. Int J Oncol. 2005; 26: 423-9.

Tian H, Gao Z, Wang G, Li H, Zheng J. Estrogen potentiates reactive oxygen species (ROS) tolerance to initiate carcinogenesis and promote cancer malignant transformation. Tumour Biol. 2016; 37: 141-50.

Zahid M, Kohli E, Saeed M, Rogan E, Cavalieri E. The greater reactivity of estradiol-3, 4-quinone vs estradiol-2, 3-quinone with DNA in the formation of depurinating adducts: Implications for tumor-initiating activity. Chem Res Toxicol. 2006; 19: 164-72.

Zahid M, Saeed M, Lu F, Gaikwad N, Rogan E, Cavalieri E. Inhibition of catechol-O-methyltransferase increases estrogenDNA adduct formation. Free Radic Biol Med. 2007; 43: 1534-40.

Sood D, Johnson N, Jain P, Siskos AP, Bennett M, Gilham C, et al. CYP3A7*1C allele is associated with reduced levels of 2-hydroxylation pathway oestrogen metabolites. British J Cancer. 2017; 116: 382-8.

Bradlow HL, Davis DL, Lin G, Sepkovic D, Tiwari R. Effects of pesticides on the ratio of 16 alpha/2-hydroxyestrone: A biologic marker of breast cancer risk. Environ Health Perspect. 1995; 103(Suppl 7): 147-50.

Lewis JS, Thomas TJ, Klinge CM, Gallo MA, Thomas T. Regulation of cell cycle and cyclins by 16alpha-hydroxyestrone in MCF-7 breast cancer cells. J Mol Endocrinol. 2001; 27: 293-307.

Lewis JS, Thomas TJ, Pestell RG, Albanese C, Gallo MA, Thomas T. Differential effects of 16alpha-hydroxyestrone and 2-methoxyestradiol on cyclin D1 involving the transcription factor ATF-2 in MCF-7 breast cancer cells. J Mol Endocrinol. 2005; 34: 91-105.

Falk RT, Manson JE, Barnabei VM, Anderson GL, Brinton LA, Rohan TE, et al. Estrogen metabolism in menopausal hormone users in the women’s health initiative observational study: Does it differ between estrogen plus progestin and estrogen alone? Int J Cancer. 2019; 144: 730-40.

Mueck AO, Ruan X, Seeger H, Fehm T, Neubauer H. Genomic and non-genomic actions of progestogens in the breast. J Steroid Biochem Mol Biol. 2014; 142: 62-7.

Anderson E. Progesterone receptors – animal models and cell signaling in breast cancer: the role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res. 2002; 4: 197.

Boonyaratanakornkit V, Bi Y, Rudd M, Edwards DP. The role and mechanism of progesterone receptor activation of extra-nuclear signaling pathways in regulating gene transcription and cell cycle progression. Steroids. 2008; 73: 922-8.

Jacobsen BM, Horwitz KB. Progesterone receptors, their isoforms and progesterone regulated transcription. Mol Cell Endocrinol. 2012; 357: 18-29.

Graham JD, Yeates C, Balleine RL, Harvey SS, Milliken JS, Bilous AM, et al. Characterization of progesterone receptor A and B expression in human breast cancer. Cancer Res. 1995; 55: 5063-8.

Hopp TA, Weiss HL, Hilsenbeck SG, Cui Y, Allred DC, Horwitz KB, et al. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res. 2004; 10: 2751-60.

Rojas PA, May M, Sequeira GR, Elia A, Alvarez M, Martinez P, et al. Progesterone receptor isoform ratio: a breast cancer prognostic and predictive factor for antiprogestin responsiveness. J Natl Cancer Inst. 2017; 109: djw317.

Mote PA, Bartow S, Tran N, Clarke CL. Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Res Treat. 2002; 72: 163-72.

Valadez-Cosmes P, Vázquez-Martínez ER, Cerbón M, CamachoArroyo I. Membrane progesterone receptors in reproduction and cancer. Mol Cell Endocrinol. 2016; 434: 166-75.

Zhu Y, Hanna RN, Schaaf MJ, Spaink HP, Thomas P. Candidates for membrane progestin receptors--past approaches and future challenges. Comp Biochem Physiol C Toxicol Pharmacol. 2008; 148: 381-9.

Kimura I, Nakayama Y, Konishi M, Terasawa K, Ohta M, Itoh N, et al. Functions of MAPR (membrane-associated progesterone receptor) family members as heme/steroid-binding proteins. Curr Protein Pept Sci. 2012; 13: 687-96.

Zhang Y, Ruan X, Willibald M, Seeger H, Fehm T, Neubauer H, et al. May progesterone receptor membrane component 1 (PGRMC1) predict the risk of breast cancer? Gynecol Endocrinol. 2016; 32: 58-60.

Ruan X, Zhang Y, Mueck AO, Willibald M, Seeger H, Fehm T, et al. Increased expression of progesterone receptor membrane component 1 is associated with aggressive phenotype and poor prognosis in ER-positive and negative breast cancer. Menopause. 2017; 24: 203-9.

Causey MW, Huston LJ, Harold DM, Charaba CJ, Ippolito DL, Hoffer ZS, et al. Transcriptional analysis of novel hormone receptors PGRMC1 and PGRMC2 as potential biomarkers of breast adenocarcinoma staging. J Surg Res. 2011; 171: 615-22.

Sitruk-Ware R. Pharmacological profile of progestins. Maturitas. 2008; 61: 151-7.

Nolan E, Vaillant F, Branstetter D, Pal B, Giner G, Whitehead L, et al. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nat Med. 2016; 22: 933-9.

Cao Y, Bonizzi G, Seagroves TN, Greten FR, Johnson R, Schmidt EV, et al. IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell. 2001; 107: 763-75.

Boopalan T, Arumugam A, Parada J, Saltzstein E, Lakshmanaswamy R. Receptor activator for nuclear factor-κB ligand signaling promotes progesterone-mediated estrogen-induced mammary carcinogenesis. Cancer Sci. 2015; 106: 25-33.

Wang HC, Lee WS. Molecular mechanisms underlying progesterone-induced cytoplasmic retention of p27 in breast cancer cells. J Steroid Biochem Mol Biol. 2018; 183: 202-9.

Boehm M, Yoshimoto T, Crook MF, Nallamshetty S, True A, Nabel GJ, et al. A growth factor-dependent nuclear kinase phosphorylates p27(Kip1) and regulates cell cycle progression. EMBO J. 2002; 21: 3390-401.

Boonyaratanakornkit V, Scott MP, Ribon V, Sherman L, Anderson SM, Maller JL, et al. Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol Cell. 2001; 8: 269-80.

Faivre E, Skildum A, Pierson-Mullany L, Lange CA. Integration of progesterone receptor mediated rapid signaling and nuclear actions in breast cancer cell models: role of mitogen-activated protein kinases and cell cycle regulators. Steroids. 2005; 70: 418-26.

Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL, et al. Progesterone induces adult mammary stem cell expansion. Nature. 2010; 465: 803-7.

Lubinski J, Huzarski T, Byrski T, Lynch HT, Cybulski C, Ghadirian P, et al. The risk of breast cancer in women with a BRCA1 mutation from North America and Poland. Int J Cancer. 2012; 131: 229-34.

Wang H-C, Lee W-S. Molecular mechanisms underlying progesterone-enhanced breast cancer cell migration. Sci. Rep. 2016; 6: 31509.

Wang HC, Huo YN, Lee WS. Folic acid prevents the progesteronepromoted proliferation and migration in breast cancer cell lines. Eur J Nutr. 2020; 59: 2333-44.

Wiebe JP. Progesterone metabolites in breast cancer. Endocr Relat Cancer. 2006; 13: 717-38.

Wiebe JP, Muzia D, Hu J, Szwajcer D, Hill SA, Seachrist JL. The 4-pregnene and 5alpha-pregnane progesterone metabolites formed in nontumorous and tumorous breast tissue have opposite effects on breast cell proliferation and adhesion. Cancer Res. 2000; 60: 936-43.

Wiebe JP, Beausoleil M, Zhang G, Cialacu V. Opposing actions of the progesterone metabolites, 5alpha-dihydroprogesterone (5alphaP) and 3alpha-dihydroprogesterone (3alphaHP) on mitosis, apoptosis, and expression of Bcl-2, Bax and p21 in human breast cell lines. J Steroid Biochem Mol Biol. 2010; 118: 125-32.

Trabert B, Falk RT, Stanczyk FZ, McGlynn KA, Brinton LA, Xu X. Reproducibility of an assay to measure serum progesterone metabolites that may be related to breast cancer risk using liquid chromatography-tandem mass spectrometry. Horm Mol Biol Clin Investig. 2015; 23: 79-84.

Khan SA. Progesterone exposure and breast cancer risk-addressing barriers. JAMA Netw Open. 2020; 3: e203608.

Cabeza M, Heuze Y, Sánchez A, Garrido M, Bratoeff E. Recent advances in structure of progestins and their binding to progesterone receptors. J Enzyme Inhib Med Chem. 2015; 30: 152-9.

Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature. 2010; 468: 98-102.

Saitoh M, Ohmichi M, Takahashi K, Kawagoe J, Ohta T, Doshida M, et al. Medroxyprogesterone acetate induces cell proliferation through up-regulation of cyclin D1 expression via phosphatidylinositol 3-kinase/Akt/nuclear factor-kappaB cascade in human breast cancer cells. Endocrinology. 2005; 146: 4917-25.

Giulianelli S, Vaqué JP, Soldati R, Wargon V, Vanzulli SI, Martins R, et al. Estrogen receptor alpha mediates progestin-induced mammary tumor growth by interacting with progesterone receptors at the cyclin D1/MYC promoters. Cancer Res. 2012; 72: 2416-27.

Diaz Flaqué MC, Vicario R, Proietti CJ, Izzo F, Schillaci R, Elizalde PV. Progestin drives breast cancer growth by inducing p21(CIP1) expression through the assembly of a transcriptional complex among Stat3, progesterone receptor and ErbB-2. Steroids. 2013; 78: 559-67.

Béguelin W, Díaz Flaqué MC, Proietti CJ, Cayrol F, Rivas MA, Tkach M, et al. Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3. Mol Cell Biol. 2010; 30: 5456-72.

Salazar M, Lerma-Ortiz A, Hooks GM, Ashley AK, Ashley RL. Progestin-mediated activation of MAPK and AKT in nuclear progesterone receptor negative breast epithelial cells: the role of membrane progesterone receptors. Gene. 2016; 591: 6-13.

Africander D, Verhoog N, Hapgood JP. Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. Steroids. 2011; 76: 636-52.

Courtin A, Communal L, Vilasco M, Cimino D, Mourra N, de Bortoli M, et al. Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells. Breast Cancer Res Treat. 2012; 131: 49-63.

Esslimani-Sahla M, Thezenas S, Simony-Lafontaine J, Kramar A, Lavaill R, Chalbos D, et al. Increased expression of fatty acid synthase and progesterone receptor in early steps of human mammary carcinogenesis. Int J Cancer. 2007; 120: 224-9.

Birrell SN, Butler LM, Harris JM, Buchanan G, Tilley WD. Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. FASEB J. 2007; 21: 2285-93.

Izuo M, Iino Y, Endo K. Oral high-dose medroxyprogesterone acetate (MAP) in treatment of advanced breast cancer. A preliminary report of clinical and experimental studies. Breast Cancer Res Treat. 1981; 1: 125-30.

Bentel JM, Birrell SN, Pickering MA, Holds DJ, Horsfall DJ, Tilley WD. Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells. Mol Cell Endocrinol. 1999; 154: 11-20.

Ganzina F. High-dose medroxyprogesterone acetate (MPA) treatment in advanced breast cancer. A review. Tumori. 1979; 65: 563-85.

Kemppainen JA, Langley E, Wong CI, Bobseine K, Kelce WR, Wilson EM. Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Mol Endocrinol. 1999; 13: 440-54.

Stanczyk FZ, Bhavnani BR. Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: is it safe? J Steroid Biochem Mol Biol. 2014; 142: 30-8.

Campagnoli C, Clavel-Chapelon F, Kaaks R, Peris C, Berrino F. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J Steroid Biochem Mol Biol. 2005; 96: 95-108.

Siddique YH, Ara G, Beg T, Afzal M. Genotoxic potential of medroxyprogesterone acetate in cultured human peripheral blood lymphocytes. Life Sci. 2006; 80: 212-8.

Siddique YH, Beg T, Afzal M. Antigenotoxic effects of ascorbic acid against megestrol acetate-induced genotoxicity in mice. Hum Exp Toxicol. 2005; 24: 121-7.

Siddique YH, Afzal M. A review on the genotoxic effects of some synthetic progestins. Int J Pharmacol. 2008; 4: 410-30.

Zhang J-W, Liu Y, Zhao J-Y, Wang L-M, Ge G-B, Gao Y, et al. Metabolic profiling and cytochrome P450 reaction phenotyping of medroxyprogesterone acetate. Drug Metab Dispos. 2008; 36: 2292.

Schoonen WG, Deckers GH, de Gooijer ME, de Ries R, Kloosterboer HJ. Hormonal properties of norethisterone, 7alpha-methyl-norethisterone and their derivatives. J Steroid Biochem Mol Biol. 2000; 74: 213-22.

Schneck H, Ruan X, Seeger H, Cahill MA, Fehm T, Mueck AO, et al. Membrane-receptor initiated proliferative effects of dienogest in human breast cancer cells. Gynecol Endocrinol. 2013; 29: 160-2.

Ruan X, Neubauer H, Yang Y, Schneck H, Schultz S, Fehm T, et al. Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells. Climacteric. 2012; 15: 467-72.

Willibald M, Bayer G, Stahlhut V, Poschmann G, Stühler K, Gierke B, et al. Progesterone receptor membrane component 1 is phosphorylated upon progestin treatment in breast cancer cells. Oncotarget. 2017; 8: 72480-93.

Guerra B, Issinger OG. Protein kinase CK2 in human diseases. Curr Med Chem. 2008; 15: 1870-86.

Ortega CE, Seidner Y, Dominguez I. Mining CK2 in cancer. PLoS One. 2014; 9: e115609.

Neubauer H, Ruan X, Schneck H, Seeger H, Cahill MA, Liang Y, et al. Overexpression of progesterone receptor membrane component 1: possible mechanism for increased breast cancer risk with norethisterone in hormone therapy. Menopause. 2013; 20: 504-10.

Zhao Y, Ruan X, Wang H, Li X, Gu M, Wang L, et al. The presence of a membrane-bound progesterone receptor induces growth of breast cancer with norethisterone but not with progesterone: a xenograft model. Maturitas. 2017; 102: 26-33.